bioequivalence studies: regulatory requirements on conduct & documentation of be

Bioequivalence studies:

Regulatory Requirements on Conduct & Documentation of BE.

Guidance & Experience.

Dr Lembit RägoCoordinator

Quality Assurance and Safety: Medicines (QSM)Medicines Policy and Standards (PSM)

WHO Headquarters, Geneva, [email protected]

Meeting on WHO Prequalification Programme on Priority Essential Medicines, WHO/EMRO

6-7 June 2007, Cairo, EGYPT

1

2

Department of Medicines Policy and Standards, Health Technology and Pharmaceuticals

History. One of the medicine's most celebrated clinical trials.

Wood engraving from 1885 showing a young patient receiving an anti-rabies vaccine developed by Louis Pasteur. A physician administers the vaccine while Pasteur, a chemist, looks on.

3


What are the problems with BE studies (I)?

BE studies – small scale clinical trials Lack of appropriate regulations Lack of ethical review/ review capacity Local industries may not have the experience and resources Lack of regulatory capacity

Lack of financial resources Lack of adequately trained human resources

Copying ICH GCP and other relevant documents from ICH regions alone does not solve the problems (regulations do not stand in vacuum…)

…

4


What are the problems (II)?

CROs increasing in middle-income developing countries Local CROs and branches of international CROs

Recent sever problems with CROs revealed by WHO inspections (in the framework of WHO prequalification programme) in some developing countries

5


WHO Glossary Contract Research organization (CRO): A scientific organization

(commercial, academic or other) to which a sponsor may transfer some of its tasks and obligations. Any such transfer should be defined in writing.

Good Clinical Practice (GCP): A standard for clinical studies which encompasses the design, conduct, monitoring, termination, audit, analyses, reporting and documentation of the studies and which ensures that the studies are scientifically and ethically sound and that the clinical properties of the pharmaceutical product (diagnostic, therapeutic or prophylactic) under investigation are properly documented.

Good Laboratory Practice (GLP)*: A quality system concerned with the organisational process and the conditions under which non-clinical health and environmental safety studies are planned, performed, monitored, recorded, archived and reported (OECD/WHO) *as applied to human bioanalysis studies

6


Handbook for Good Clinical Research Practice (GCP)World Health Organization 2005

Structured as 14 principles, 115 pages Serves as and adjunct to WHO's GCP

from 1995, and subsequent ICH GCP Contains CD version with all major

reference documents as hyperlinks

7


Bioequivalence studies

Products to be prequalified usually multisource (generic) products

Therapeutic equivalence generally demonstrated by bioequivalence study in CROs

Findings of deficient and discrepant bioequivalence data and non-compliance with norms and standards for GCP (WHO) and GLP (WHO GPNPCL, and OECD/WHO as appropriate)

8


What resources are available to assist proper conduct of BE studies from WHO (I)?

Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability (1)

Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms (2)

Additional guidance for organizations performing in vivo bioequivalence studies (3)

Guidance on the selection of comparator pharmaceutical products for equivalence

assessment of interchangeable multisource (generic) products (4) "Note to applicants on the choice of comparator products for the

prequalification project” (see WHO PQ web site - 5) WHO Public Inspection reports of CROs (see PQ web site - 6) WHO Training courses (see materials of previous courses on PQ web

site) … advise to manufacturers applying for prequalification

9


WHO Documents

The Expert Committee documents pass wide international consultation and are finally adopted by the Committee composed of outstanding inernational technical experts

10


11.1

11


1.2

12


2

13


3.1

14


3.2

15


4

16


5

17


6.1

18


6.2

19


What is WHO doing re ETHICS?

Operational Guidelines for Ethics Committees that Review Biomedical Research (TDR/PRD/ETHICS/2000.1)

http://www.who.int/tdr/publications/publications/pdf/ethics.pdf

Surveying and Evaluating Ethical Review Practices: a complementary guideline to the Operational Guidelines for Ethics Committees that Review Biomedical Research (PUB: TDR/PRD/ETHICS/2002.1)

http://www.who.int/tdr/publications/publications/pdf/ethics2.pdf

20


CRO inspections - areas covered

ClinicalGeneral organization, the protocol, protection of trial subjects, responsibilities of the investigator, responsibilities of the sponsor/monitor, record-keeping and handling of data, handling and accountability for pharmaceutical products, quality assurance for the conduct of a clinical trial

Bio-analyticalApparatuses/material/reagents, SOPs, performance of the study, test and reference items, storage and retention of records and materials, quality assurance

PK analysis and statistics

Reporting

21


Examples of findings

Based on CRO inspections performed by WHO

Inspections study-specific

Team of 3 inspectors (2 WHO team + national inspector as observer)

Based on 6 CROs inspected

22


Findings. General organization.

Transfer of responsibilities from sponsor to CRO not documented

Unclear procedure for assigning Subject ID (two subjects assigned the same ID on the Attendance Sheet Form!)

No SOP for drug dispensing No SOP for assigning study numbers No trial site staff sample signature log for the study Organization chart not readily available, no version date No QC system to ensure accuracy and consistency in recording

and document control

23


Findings. The protocol (II)

Validity of screening tests? No CRFs designed for the study (raw data not transferred to

CRFs)

Not included: Name and address of sponsor Description of trial site and information on investigators Method and procedure of randomisation, randomisation

schedule and how it was established Method and timing of subject allocation to investigational groups

24


Findings. The Protocol, cont. (III)

Not included: Information to volunteers (informed consent) Procedures for maintaining subject identification code list Statistical justification for the number of subjects Method for measuring blood pressure - sitting or supine? And if

both, which value to use… Type of test tubes for blood sampling PK analysis; Method of calculating PK pararmeters, e.g. AUC,

how to deal with deviations from planned sampling times How to evaluate the results, including statistics and how to

handle withdrawals

25


Responsibilities of the Sponsor/Monitor

No monitors appointed by the sponsor. No monitoring/audit reports available.

No evidence of assessment of the trial site (labs, equipment, staff, facilities)

Audits performed by the sponsor, but scheduled after the report was issued and no audits' reports available

Issues with certificate of insurance subscribed by the CRO

26


Record-keeping and handling of data

No study or protocol number on ECGs to link them to the study. Of 95 ECGs copied by inspectors, 43 appeared to have been

recorded from one subject, 21 from a second subject and 11 from a third subject (i.e. in total 75 ECGs from 3 persons!).

For several subjects the "screening" and "follow up" ECGs appeared to have been recorded from different subjects

No mention on ECG print outs of the identity of the equipment used

Some ECGs had no date of birth of subject

Doubts as to the authenticity of ECG documentation!

27


Record-keeping and handling of data (continued)

No mention of name, batch no or expiry date of the in vitro diagnostic serology test kit in source doc's or lab data

Discrepancies between Attendance Sheet Forms and CRF Screening pages (screening visit dates)

Discrepancies between Volunteer Card and CRF (smoking/alcohol) Unclear dosing time Identical (actual) blood sampling times for two subjects! Recordings of actual sampling times - same handwriting, however

initials of phlebotomists different at different sampling times! Deviations from planned blood sampling times not reported Inconsistencies in screening dates

28


Record-keeping and handling of data (continued)

Deliberate attempt to change subject code Discrepancies between source documents and study report Method/procedure of randomization not documented No record of subjects screened Source documents not kept Original entry erased! Type of tubes and anticoagulant used not documented CRF (IPΦ) used was not specific to the study Errors on the CRFs Expiry date of medications not recorded on CRFs Appearance of tablets incorrectly described Missing: Lab data, ECG… Final study report not signed by the monitor …

29


Bioanalytical. Test and reference items

Batch numbers of reference substances used not documented – were the batches used, those for which CAs were available?

Not possible to verify purity of reference substances used!

30


Reporting.(OECD GLP 2 & 9)

Same or different stock solution for calibration/control samples?

Some zidovudine conc's were lamivudine conc's Discrepancy between concentration on chromatogram and

in study report Composition of buffer for sample preparation not in SOP Errors in the bioanalytical report Rounding errors

31


What is WHO doing regarding Ethics?

Operational Guidelines for Ethics Committees that Review Biomedical Research (TDR/PRD/ETHICS/2000.1)

http://www.who.int/tdr/publications/publications/pdf/ethics.pdf

Surveying and Evaluating Ethical Review Practices: a complementary guideline to the Operational Guidelines for Ethics Committees that Review Biomedical Research (PUB: TDR/PRD/ETHICS/2002.1)

http://www.who.int/tdr/publications/publications/pdf/ethics2.pdf

32


BSC based bio-waiver: a long way from concept to practice

1995 FDA – SUPAC guidance

1996 WHO – Interchangeability guideline - cautious and vague attitude

1999 WHO – "Blue book" – cautious recognition of BCS potential, no change in reserved position

2000 FDA – Guidance on BA and BE waiver based on BCS, deals with INDs/NDAs, ANDAs and post-approval changes

2001 EU – Note for guidance on BA and BE – takes BCS into consideration

2006 WHO – Interchangeability guideline and specific BCS guideline proposing the implementation of BCS approach

33


WHO Technical Report Series, No. 863, 1996WHO Technical Report Series, No. 863, 1996

Annex 9 Multisource (generic) Pharmaceutical Products:

Guidelines on Registration Requirements to Establish Interchangeability.

34


WHO Technical Report Series, No. 863, 1996 WHO Technical Report Series, No. 863, 1996

Annex 9, Part III – Tests for equivalence Section 13: In vitro dissolution Comparative in vitro dissolution studies may be useful in

the documentation of equivalence between two multisource pharmaceutical products. However because of the many limitations associated with the use of in vitro dissolution in the documentation of equivalence it is recommended in these guidelines that its application for this purpose should be kept to a minimum.

35


WHO Technical Report Series, No. 863, 1996WHO Technical Report Series, No. 863, 1996

Annex 9, Part III, Section 13: In vitro dissolution In vitro dissolution testing … should be reserved for rapidly

dissolving drug products. When the multisource test and reference products both dissolve with sufficient rapidity (e.g. >80% in 15 minutes) their in vivo equivalence may be presumed. Approval of multisource formulations by the use of comparative in vitro dissolution studies should be based on the generation of comparative dissolution profiles rather than single-point dissolution tests … Multiple dissolution test conditions and physiologically relevant media are recommended.

36


Chronology of BCS implementationChronology of BCS implementation

1995 FDA – SUPAC guidance

1996 WHO – Interchangeability guideline - cautious and vague attitude

1999 WHO – "Blue book" – cautious recognition of BCS potential, no change in reserved position

2000 FDA – Guidance on BA and BE waiver based on BCS, deals with INDs/NDAs, ANDAs and post-approval changes

2001 EU – Note for guidance on BA and BE – takes BCS into consideration

2006 WHO – Interchangeability guideline and specific BCS guideline proposing the implementation of BCS approach

37


WHO Technical Report Series, No. 937, 2006 Annex 7


Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability.

Intended to provide recommendations to sponsors and national regulatory authorities on in vivo and vitro requirements to assure interchangeability of multisource medicinal products without compromising quality, safety and efficacy.

http://www.who.int/medicines/publications/pharmprep/TRS_937.pdf

38




Section 9: In vitro testing Over the past three decades, dissolution testing has

evolved into a powerful tool for characterising the quality of oral pharmaceutical products. The dissolution test … is now emerging as a surrogate equivalence test for certain categories of orally administered pharmaceutical products. For these products (typically solid oral dosage forms containing APIs with suitable properties) a comparative in vitro dissolution profile similarity can be used to document equivalence of a multisource with a comparator product.

39




Section 9: In vitro testing 9.1 In vitro testing and the Biopharmaceutical Classification

System 9.1.1 Biopharmaceutics classification system

High solubility High permeability

9.1.2 Determination of dissolution characteristics of multisource products in consideration of a biowaiver based on BCS Very rapidly dissolving Rapidly dissolving

40


WHO Technical Report Series, No. 937, 2006 Annex 7WHO Technical Report Series, No. 937, 2006 Annex 7

Section 9: In vitro testing 9.2 Qualification for a biowaiver based on BCS 9.2.1 Dissolution criteria for biowaivers based on the BCS

according to the properties of active pharmaceutical ingredients

41




Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms".

Intended to give national regulatory authorities information on orally administered APIs on WHO Model List of Essential Medicines whether biovaiwer can be granted for generic formulations.

http://www.who.int/medicines/publications/pharmprep/TRS_937.pdf

42



WHO revisions to the criteria for BCS classification High solubility: max 250ml at 37C over pH 1.2-6.8

FDA - pH 1-7.5 EMEA - pH 1-8, preferably 1, 4.6 and 6.8

Highest strength (dose): according to Essential Medicines List (14th EML 2005)

Permeability: absorbed at least from 85% FDA - 90% or more EMEA – linear and complete absorption

43



WHO extensions to the scope of application of biowaiver Class I APIs classification criteria relaxed - both solubility and

permeability Class II weak acidic APIs eligible for biowaiver, if

soluble in 250 ml or less at pH 6.8 rapid dissolution at pH 6.8 similar dissolution profiles (f2) to comparator at pH 1.2, 4.5 and 6.8

Class III APIs eligible for biowaiver, if very rapid dissolution

44


BCS according to WHOBCS according to WHO

Absorbed >85%

CLASS IHighly permeableHighly soluble (very rapid dissolutionor profile comparison)Eligible

CLASS IIIPoorly permeableHighly solubleEligible if veryrapidly dissolving

CLASS IIHighly permeablePoorly solubleEligible only if theD:S at pH 6.8 is 250ml or lower*

CLASS IVPoorly permeablePoorly soluble

Not eligible

Solubility at pH 1-6.8

45



3 Tables of APIs non-complementary orally administered EML APIs complementary EML APIs newly /2005/ classified APIs

In case of incomplete data APIs classified conservatively ("worst case" approach)

Potential risks, indications (EML) and comments included to support risk assessment and decision making

46



47


Conclusions

QUALITY first, only then BE For many developing country manufacturers BE studies a

"bottleneck" Need to start implementing BSC based biowaiver in PQ

Programme step-by-step Need for additional guidance and training re BE and

BSC/dissolution based biowaiver